Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference

被引:46
作者
Hassan, R.
Alexander, R.
Antman, K.
Boffetta, P.
Churg, A.
Coit, D.
Hausner, P.
Kennedy, R.
Kindler, H.
Metintas, M.
Mutti, L.
Onda, M.
Pass, H.
Premkumar, A.
Roggli, V.
Sterman, D.
Sugarbaker, P.
Taub, R.
Verschraegen, C.
机构
[1] Natl Canc Inst Hlth, Bethesda, MD USA
[2] Int Agcy Res Canc, F-69372 Lyon, France
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Univ Maryland, College Pk, MD 20742 USA
[6] Texas Tech Univ, Ctr Hlth Sci, Lubbock, TX 79409 USA
[7] Univ Chicago, Chicago, IL 60637 USA
[8] Osmangazi Univ, Eskisehir, Turkey
[9] Local Hlth Unit 11, Vercelli, Italy
[10] Karmanos Canc Inst, Detroit, MI USA
[11] Duke Univ, Med Ctr, Durham, NC 27706 USA
[12] Univ Penn, Philadelphia, PA 19104 USA
[13] Washington Hosp Ctr, Washington, DC 20010 USA
[14] Columbia Univ, New York, NY 10027 USA
[15] Univ New Mexico, Albuquerque, NM 87131 USA
关键词
cancer; mesothelioma; peritoneal;
D O I
10.1093/annonc/mdl060
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.
引用
收藏
页码:1615 / 1619
页数:5
相关论文
共 24 条
[1]
Churg A, 2000, AM J SURG PATHOL, V24, P1183
[2]
DAYA D, 1990, CANCER-AM CANCER SOC, V65, P292, DOI 10.1002/1097-0142(19900115)65:2<292::AID-CNCR2820650218>3.0.CO
[3]
2-W
[4]
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy [J].
Feldman, AL ;
Libutti, SK ;
Pingpank, JF ;
Bartlett, DL ;
Beresnev, TH ;
Mavroukakis, SM ;
Steinberg, SM ;
Liewehr, DJ ;
Kleiner, DE ;
Alexander, HR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4560-4567
[5]
Freedman RS, 2003, CLIN CANCER RES, V9, P5228
[6]
Mesothelin: A new target for immunotherapy [J].
Hassan, R ;
Bera, T ;
Pastan, I .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :3937-3942
[7]
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma [J].
Kindler, HL .
LUNG CANCER, 2004, 45 :S125-S127
[8]
Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity [J].
Krist, LFG ;
Kerremans, M ;
Broekhuis-Fluitsma, DM ;
Eestermans, IL ;
Meyer, S ;
Beelen, RHJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (04) :205-212
[9]
MAURER R, 1975, CANCER, V36, P1381, DOI 10.1002/1097-0142(197510)36:4<1381::AID-CNCR2820360429>3.0.CO
[10]
2-X